Influence of an Omega-3 SPM Supplement on Quality of Life

Exclusion Criteria

• •Initiation of or changes in use of fish oil supplements, krill oil supplements, omega 3 supplements, or omega 3-based drugs (Lovaza®, etc.) within the past 3 months
• •Initiation of new pain medications and non-steroidal anti-inflammatory drugs NSAIDS within the past month such as \[aspirin, ibuprofen (Advil®, Motrin®, Nuprin®), acetaminophen (Tylenol®), naproxen (Aleve®, Naprosyn®), codeine (Vicodin®), morphine (Dilaudid®), oxycodone (OxyContin®, Percocet®) fentanyl (Duragesic®) and COX-2 inhibitors, Celebrex®)
• •Currently taking:
• •* Medication to reduce the tendency to form blood clots such as \[warfarin, jantoven (Coumadin®); dabigatran (Pradaxa®); rivaroxaban, (Xarelto®); apixaban (Eliquis®)\]
• •* Statin use for cholesterol reduction such as \[atorvastatin (Lipitor®), fluvastatin (Lescol®), lovastatin (Mevacor®, Altocor®), pitavastatin (Livalo®), pravastatin (Pravachol®), rosuvastatin (Crestor®) or simvastatin (Zocor®)\] (not including Red Yeast Rice if also supplementing with CoQ10)
• •* Corticosteroids such as \[prednisone, dexamethasone, prednisolone (Orapred®, Prelone®, Pediapred®), methylprednisolone (Medrol®)\] (not including topical corticosteroids for dermatological conditions or nasally inhaled for asthma, rhinitis or sinusitis)
• •* Daily aspirin \>325 mg per day (not including low dose aspirin therapy of 81 mg - 325 mg per day)
• •Other medications and supplements to be evaluated by the investigators on a case-by-case basis
• •Steroid injections, Prolotherapy, or other injections into a ligament, tendon, joint or muscle during the past month or initiation or continuation of therapy injections during the course of the study.
• •Present or past history of any of the following:
• •* Inflammatory disease (e.g. rheumatoid arthritis, autoimmune disease, Crohn's disease, diverticulitis, viral hepatitis, ulcerative colitis, systemic lupus, Parkinson's disease, Alzheimer's, ankylosing spondylitis)
• •* Blood clot disorder (e.g., phlebitis)
• •* Diabetes (self-report; includes Type I and Type II Diabetes but does not include a history of Gestational Diabetes during pregnancy)
• •* Cancer within the last 5 years (with the exception of basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix)
• •* Cardiovascular disease within the last year, including but not limited to: myocardial infarction, stroke, congestive heart failure (CHF)
• •* Kidney failure or liver failure
• •Current active pelvic inflammatory disease, urinary tract infection or a kidney infection
• •Women who are lactating, pregnant or planning pregnancy within the next six months
• •Difficulty or aversion to swallowing soft gels, capsules, tablets or pills
• •Known intolerance or allergy to fish oils
• •Upon administering the NCNM Adverse Event Monitoring form at screening, a sign or symptom of Grade 3 (severe or medically significant but not immediately life-threatening) or higher is reported
• •Currently participating in another research study or participated in another study within the last month